FogPharma hauls in $178M series D, the company’s second consecutive nine-digit financing round

Coming off a $107 million series C round in March 2021, FogPharma spirits were high and aspirations for its “universal druggability” platform were through the roof. Now, the company has even more reason to be confident, closing a new gargantuan funding round.